Preoperative SGLT-2 inhibitor use and risk of adverse postoperative events: a single-centre retrospective observational study.
作者信息
Tenge Theresa, Roth Sebastian, Ahrens Elena, Wachtendorf Luca J, Paschold Béla-Simon, Chen Guanqing, M'Pembele René, Kindgen-Milles Detlef, Katsiampoura Anastasia, Kienbaum Peter, Buse Giovanna Lurati, Schaefer Maximilian S
机构信息
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
出版信息
Br J Anaesth. 2025 Apr;134(4):1214-1217. doi: 10.1016/j.bja.2024.12.024. Epub 2025 Jan 24.
Abstract
摘要
相似文献
1
Preoperative SGLT-2 inhibitor use and risk of adverse postoperative events: a single-centre retrospective observational study.术前使用钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与术后不良事件风险：一项单中心回顾性观察研究
Br J Anaesth. 2025 Apr;134(4):1214-1217. doi: 10.1016/j.bja.2024.12.024. Epub 2025 Jan 24.
2
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的早期应用的理由。
Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23.
3
Euglycemic Ketoacidosis Associated with SGLT-2 Inhibitors in Non-diabetic Patients-A Narrative Review.非糖尿病患者中与SGLT-2抑制剂相关的正常血糖性酮症酸中毒——一篇叙述性综述
J Gen Intern Med. 2025 Feb;40(2):437-442. doi: 10.1007/s11606-024-09073-2. Epub 2024 Oct 1.
4
Management of sodium-glucose cotransporter 2 inhibitors during the perioperative period: A retrospective comparative study.围手术期钠-葡萄糖共转运蛋白 2 抑制剂的管理：一项回顾性对比研究。
J Perioper Pract. 2021 Oct;31(10):391-398. doi: 10.1177/1750458920948693. Epub 2020 Sep 8.
5
The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂在 2 型糖尿病心力衰竭和慢性肾脏病中的作用。
Curr Med Res Opin. 2019 Jul;35(7):1283-1295. doi: 10.1080/03007995.2019.1576479. Epub 2019 Feb 15.
6
Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭患者中的不良反应：系统评价和荟萃分析。
Heart Fail Rev. 2024 Jan;29(1):207-217. doi: 10.1007/s10741-023-10363-w. Epub 2023 Nov 2.
7
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用：超越 2 型糖尿病。一篇叙述性综述。
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
8
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂治疗慢性肾脏病成人患者：临床实践指南。
BMJ. 2024 Oct 1;387:e080257. doi: 10.1136/bmj-2024-080257.
9
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.钠-葡萄糖共转运蛋白 2 抑制剂在无心血管和肾脏疾病的日本 2 型糖尿病患者中的使用与较低的心衰和慢性肾脏疾病风险相关。
Diabetes Obes Metab. 2021 Apr;23 Suppl 2:19-27. doi: 10.1111/dom.14119.
10
Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate.2型糖尿病合并估算肾小球滤过率降低患者中钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂的处方率
Innov Pharm. 2023 Oct 10;14(2). doi: 10.24926/iip.v14i2.5456. eCollection 2023.
本文引用的文献
1
Update on the perioperative management of diabetes mellitus.糖尿病围手术期管理的最新进展
BJA Educ. 2024 Aug;24(8):261-269. doi: 10.1016/j.bjae.2024.04.007. Epub 2024 May 31.
2
Risk of perioperative discontinuation of SGLT2 inhibitors.SGLT2 抑制剂围手术期停药风险。
Br J Anaesth. 2024 Aug;133(2):239-240. doi: 10.1016/j.bja.2024.05.004. Epub 2024 Jun 4.
3
Sodium-glucose cotransporter-2 inhibitors in non-diabetic patients: is there a perioperative risk of euglycaemic ketoacidosis.非糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂：是否存在围手术期正常血糖性酮症酸中毒风险。
Br J Anaesth. 2024 Feb;132(2):435-436. doi: 10.1016/j.bja.2023.11.015. Epub 2023 Dec 4.
4
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.《2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南》2023年聚焦更新
Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195.
5
Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis.SGLT2 抑制剂持药时间与术后阴离子间隙酸中毒风险的剂量依赖性关系：单中心回顾性分析。
Br J Anaesth. 2023 Oct;131(4):682-686. doi: 10.1016/j.bja.2023.06.063. Epub 2023 Aug 2.
6
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.达格列净治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
7
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e876-e894. doi: 10.1161/CIR.0000000000001062. Epub 2022 Apr 1.
8
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.SGLT2 抑制剂与 2 型糖尿病患者心血管和肾脏结局的关联：一项荟萃分析。
JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.
9
Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.与钠-葡萄糖共转运蛋白 2 抑制剂相关的围手术期糖尿病酮症酸中毒：系统评价。
Br J Anaesth. 2019 Jul;123(1):27-36. doi: 10.1016/j.bja.2019.03.028. Epub 2019 May 3.
10
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Zotero 插件